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Abstract
In cattle, the serum protein haptoglobin (Hp) is a major acute phase protein (APP) that rises in concentration over a thousand fold
following stimulation by pro-inflammatory cytokines. As such, this APP is a valuable biomarker for infection, inflammation and
trauma in cattle. The assay for bovineHp is becomingmore commonplace in clinical pathology and in experimental studies when a
biomarker of innate immunity is required. The most widely used assay for Hp utilises its binding to haemoglobin (Hp-Hb binding
assay), which at low pH enables the preservation of the native peroxidase activity in the haemoglobin. This assay is used for all
species, including species such as dog, cat and pig where the level of Hp is higher in healthy animals of these species than in
healthy cattle, and therefore a bovine-specific immunoassay that can be automated would be desirable. Thus, a novel-automated
species-specific immunoturbidimetric (IT) assay has been developed. Validation studies showed intra- and inter-assay CVs of
below 5% and 9% respectively and a recovery of 99% from samples spiked with bovine Hp and a limit of quantification of
0.033 g/L. The assay is not affected by icterus or lipaemia but had moderate interference from haemoglobin and showed a
significant correlation with the Hp-Hb binding assay. This novel IT assay for bovine Hp will allow automated analysis of this
important bovine APP to identify changes in the Hp concentration not detectable by current Hp-Hb binding assays. It will enable
the incorporation of this assay into herd health assessments, animal welfare analysis and for bovine medicine and research.
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Introduction
Haptoglobin (Hp) is a serum protein that in many species is an
acute phase protein (APP), increasing in concentration during
innate immune responses to infection, inflammation and trau-
ma (Ceron et al. 2005; Cray et al. 2009; Eckersall and Bell
2010). Acute phase proteins are stimulated by pro-
inflammatory cytokines such as interleukin (IL)-1, IL-6 and
tumour necrosis factor-α (Moshage 1997). It has been
demonstrated that measurement of the circulating concentra-
tion of Hp provides valuable diagnostic information on the
host’s innate immune responses with over 1000-fold increases
occurring in some species such as cattle and sheep where it is
classified as a major APP (Ceciliani et al. 2012; Horadagoda
et al. 1999). Haptoglobin is also a valuable serum biomarker
in species such as dogs, pigs and human where increases may
only be up to 10-fold the resting levels, where it is classified as
a moderate APP. As a biomarker of innate immune responses,
the increased serum concentrations of APP reflect active dis-
ease processes and, although they are not specific for particu-
lar diseases, they are highly sensitive indicators of pathologi-
cal processes following infection or inflammation across vet-
erinary species (O’Reilly and Eckersall 2014; Schmidt and
Eckersall 2015). Thus, over recent decades, the measurement
of serum Hp in a variety of species has become more com-
mon, and there have been extensive reports of the use of mea-
suring this APP in investigations of both experimental and
clinical studies (Eckersall and Bell 2010). In cattle, raised
serum Hp has been demonstrated in diseases of respiratory,
reproductive, digestive and mammary functions and has also
been identified as a biomarker of peri-parturient disease
(Ceciliani et al. 2012).
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The analysis of serum Hp for analysis in comparative clin-
ical pathology was facilitated by the development of a bio-
chemical assay based on the biological activity of Hp binding
to haemoglobin (Hp-Hb binding assay) (Eckersall et al. 1999).
This assay format led to the automation of the assay on bio-
chemical analysers which are located in most veterinary diag-
nostic laboratories. While the Hp-Hb binding assay is a valu-
able diagnostic test to use on a biochemical analyser and can
detect and quantify increased levels of Hp in species where it
undergoes an APP response, there are problems inherent when
measured on certain biochemical analysers that can lead to
reduced precision. The Hp-Hb binding assay was developed
for analysers which operate with three reagents and the Hp-
Hb binding assays have three reagents, namely (i) a solution
of haemoglobin, (ii) a chromogen, which is a peroxidase sub-
strate in buffer and (iii) peroxide. In recent years, many bio-
chemical analysers are used in veterinary laboratories which
accommodate only two reagents. The Hp-Hb binding assay
can only be used on these analysers if two of the reagents are
mixed, such as a mix of the chromogen (containing a peroxide
substrate) and peroxide, or a mix of peroxide and haemoglobin
which has an innate peroxidase activity. Both of these mixtures
are inherently unstable and have a short shelf life so if not used
immediately can cause poor precision.
To measure proteins in human serum in clinical biochemistry
laboratories, at similar concentrations as found in bovine serum
for Hp, the method of choice is by immunoturbidimetric (IT)
assays (Eckersall et al. 1991; Ledue et al. 2002; Price et al.
1983). These are immunoassays based on antibody-antigen in-
teraction and are rapid as well as being specific and sensitive and
only require two reagents being assay buffer and an antibody
solution. Therefore, the aim of this study was to develop an IT
assay for bovineHp, based on species-specific antiserum that can
be used in all biochemical analysers, including those that are
designed to only use two reagents, and to compare its function
to an established Hp-Hb binding assay (Eckersall et al. 1999).
Materials and methods
Antiserum to bovine haptoglobin (Life Diagnostics Inc., West
Chester, USA) raised in sheep (Diagnostic Scotland,
Edinburgh, UK) was used in the development of the IT assay.
The IT assay was set up on an ABX Pentra 400 automated
biochemical analyser (HORIBAUKLtd., Northampton, UK),
initially using parameters based on those previously described
for canine C-reactive protein (Eckersall et al. 1991) using a
pool of bovine serum with high Hp as standard, which was
calibrated against the International Reference Preparations of
bovine serum archived at the University of Copenhagen (Prof.
P. Heegaard). Standards were prepared by dilution of the pool
of high Hp (1.49 g/L), to give further Hp concentrations of
1.18, 0.57, 0.027 and 0.00 g/L. The diluent was ovine serum
in order to minimise matrix effects caused by the use of buffer
alone as diluent. The optimised assay protocol consisted of
5 μL of sample or standard added to 150 μL of 4% (w/v)
polyethylene glycol 8000 (Sigma) in 20 mM pH8.0 Tris buff-
ered saline (TBS) with 1.0% (w/v) Tween 20, and 10 μL
distilled water, followed by the addition of 35 μL of sheep
anti-bovine Hp antiserum at 48 s and run for a total of 300 s
with absorbance being monitored at 340 nm. The concentra-
tion of Hp in samples was determined against the standard
curve using a 4-parameter fit model in the integrated computer
system of the biochemical analyser.
Laboratory validation of the IT Hp assay was performed to
determine specificity, precision, accuracy, limit of detection
and interference following Hillstrom et al. (2014) and
Piñeiro et al. (2018). The specificity of the antiserum was
assessed by Ouchterlony agarose gel immunodiffusion in a
1% (w/v) agarose gel prepared in 20 mM pH 7.4 TBS. The
centre well contained sheep anti-bovine Hp antiserum as used
in the IT assay. Commercially available purified bovine hap-
toglobin with a Hp concentration of 0.84 g/L (Life
Diagnostics Inc., West Chester, USA) and bovine serum sam-
ples with different Hp concentrations (1.49, 1.18, 0.57, 0.027
and 0.00 g/L), as determined by the Hp-Hb binding assay,
were placed in the outer wells.
The precision of the assay was determined by analysing low,
medium and high Hp serum samples six times each in the same
assay run to determine the intra-assay coefficient of variance
(CV). For the inter-assay CV low, medium and high Hp serum
samples were run individually over six consecutive days.
Accuracy was assessed by spiking the zero standard with
commercially available purified bovine haptoglobin (Life
Diagnostics Inc. West Chester, USA). This was serially diluted
1:2, 1:4, 1:8 and 1:16, and each dilution was measured in trip-
licate. The percentage recovery was calculated for each dilu-
tion. A low and a high Hp serum sample were diluted 1:2 and
1:4 to determine the linearity of the assay and parallelism to the
standard curve. Each dilution was measured in triplicate.
To determine operation of the IT assay with low concentra-
tions of Hp the approaches described by Hillstrom et al.
(2014) and Piñeiro et al. (2018) were used. The zero standard
(ovine serum) was measured 12 times in a single run in order
to calculate the limit of blank, calculated as the mean of the
zero standard (μb) plus three standard deviations of the blank
(σb). The Limit of Detection was determined bymeasuring the
standard deviation of replicates (n = 8) of a sample with low
concentration of Hp (σs). The Limit of Detection (LoD) was
calculated (Piñeiro et al. 2018) as
LoD ¼ μb þ 1:645σb þ 1:645σs
The Limit of Quantitation (LoQ) was determined by mea-
suring the Hp in replicates of dilutions of a low Hp bovine
sample (1:8, n = 8; 1:16, n = 15 over 2 runs; 1:32, n = 14 over
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2 runs, 1:64 n = 1) and was the lowest concentration when the
total error (TE) was lower than the allowable total error (TEa)
set at 29.6% (Hillstrom et al. 2014).
For interference studies, a stock solution containing 30 g/L
of haemoglobin (Eckersall et al. 1999) was used to spike a
high Hp serum sample with increasing concentrations of
haemoglobin (0.031 to 4 g/L). To determine the interference
from bilirubin, the metabolite was added to bovine serumwith
a high level of Hp, at concentrations of bilirubin from 1.56 to
50 mM. To determine the effect of lipaemia, Intralipid (Sigma
Chem Co, Poole, UK) was used to spike a high Hp serum
sample to give samples with a final triglyceride concentration
of 1.08–50 g/L respectively. Each sample for the interference
studies was measured in triplicate.
For comparison to an established Hp-Hb binding assay
(Eckersall et al. 1999), bovine serum samples (n = 182) were
analysed for Hp with results from both assays compared. The
Hp-Hb binding method was performed as described by
Eckersall et al. (1999) with minor modifications. The chromo-
gen reagent was altered by use of an alternative peroxidase
substrate, SAT-3 an o-tolidine analogue, which after oxidation
has an absorbance maximum at 660 nm, by replacement of
dithioerythritol with cysteine as a reducing agent and by using
triclosan as an anti-bacterial agent. The haemoglobin solution
and peroxide reagent remained the same as previously de-
scribed (Eckersall et al. 1999).
The final working concentrations in the reagents were as
follows. Hb reagent was 60 mg/L of Hb 0.154 M NaCl. The
chromogen reagent was prepared in 60 mM citric acid and
100 mM di-sodium phosphate at pH 3.8 containing 20 mM
phenol, 3.6 mM L-cysteine, 0.32 mM SAT-3 (NBS
Biologicals Ltd., Cambridge, UK, Dojindo Inc., Japan), 1%
(v/v) Tween 20 and 0.001% w/v triclosan. The substrate per-
oxide reagent was 0.12% (v/v) H2O2 diluted from a stock of
30% H2O2. Chemicals were obtained from Sigma-Aldrich Co
Ltd., Poole, UK, unless otherwise stated.
The assay was performed on the ABX Pentra 400 (Horiba
UK Ltd., Northampton, UK) automated biochemical analyser
with incubation at 37 °C and was calibrated with a pool of
porcine serumwithHp concentration of 1.4 g/L determined by
comparison to the International Reference Preparations of bo-
vine serum from the University of Copenhagen (Prof. P.
Heegaard). Sample or standard (3 μL) was mixed with
100 μL of Hb reagent and after mixing, 50 μL of chromogen
reagent was added. After further mixing, 40 μL of peroxide
reagent was added and the absorbance was measured after
5 min at 660 nm. Standards of Hp at 1.4, 0.7, 0.35 and 0 g/L
were run in each assay and used for calculation of the Hp
concentration in each sample using a four-parameter fit model
on the computer system of the biochemical analyser.
For comparison between this established assay and the novel
IT, serum samples were run in both assays using residual bovine
serum samples collected from adult dairy cows by the University
of Edinburgh Royal (Dick) School of Veterinary Studies
Langhill dairy farm (UK), collected as part of their annual
Johnes Disease accreditation test. Their use in this study follow-
ed ethical approval by the Royal (Dick) School of Veterinary
Studies Veterinary Ethical Review Committee Ref 32-17. The
comparison between assays was initially performed on samples
(n = 108) that had a Hp concentration above the limit of quanti-
fication of the Hp-Hb binding assay of 0.03 g/L.
Statistical analysis was performed using Graphpad Prism ver-
sion 6 (Graphpad Software Inc. CA,USA) to calculatemean, SD
and CV, for regression analysis and the Bland-Altman analysis.
Results
The specificity of the assay depends on the reactivity of the
antiserum to bovine Hp, which was determined in the immu-
nodiffusion gel shown in Fig. 1. Bands of precipitation were
detected when sheep anti-bovine Hp antiserum reacted with
purified bovine Hp and bovine serum samples containing Hp.
The continuous lines of precipitation indicate that the antigen
in the bovine serum samples being measured was bovine Hp.
No precipitation was observed around the wells containing
bovine serum with undetectable Hp.
Fig. 1 Immunodiffusion in agarose gel. Centre well contained: A: sheep
anti-bovine antiserum. Outer wells contained 1: purified bovine Hp at
0.84 g/L; 2: bovine serum containing 1.49 g/L of Hp; 3: bovine serum
containing 1.18 g/L of Hp; 4: bovine serum containing 0.57 g/L of Hp; 5:
bovine serum containing 0.27 g/L of Hp; 6: bovine serum containing
0.00 g/L of Hp
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The precision of the Hp ITassay is given in Tables 1 and 2,
with intra-assay CV of 4.1% and 5.0% at low and high QC
sample. Inter-assay CVs were 7.4% for a low QC sample and
8.1% for the high QC sample.
The accuracy of the Hp ITassay determined by recovery of
added Hp to a sample serum with an undetectable concentra-
tion gave a mean recovery of 99% (Table 3), ranging from
76% at the expected value of 0.12 g/L to 112% at an expected
0.47 g/L. The recovery is depicted in Fig. 2, with the relation
between observed and expected Hp concentrations giving a
correlation coefficient (R2) of 0.99.
The linearity of the dilution of a sample of high Hp con-
centration diluted in a serum of negligible Hp concentration
showed the dilution curve given in Fig. 3, with a correlation
coefficient (R2) of 0.99 and a regression equation of Observed
Hp (y) = 1.02 Expected Hp (x) + 0.0031.
The interference in the Hp IT assay caused by Hb showed
there was no effect up to a level of 0.5 g/L of Hb in the serum,
with a gradual effect thereafter with a 10% reduction in the Hp
result at a level of 4 g/L of Hb in the serum (Fig. 4a). Bilirubin
had a minimal effect on the IT Hp assay up to a concentration
of 50 mM (Fig. 4b). Lipaemia did not cause any change in the
measured Hp concentration (Fig. 4c). The limit of blank of the
Hp IT assay was calculated to be 0.011 g/L being the Hp
concentration at 3 SD from the mean of the blank sample,
the limit of detection was 0.018 g/L and the limit of quantifi-
cation was 0.033 g/L (Table 4).
In comparison to the previously established Hp-Hb binding
assay, the novel IT assay gave a correlation coefficient (R2) of
0.95 with a regression equation of y = 0.98x + 0.09 (y =Hp in
the IT assay; x =Hp by the Hp-HB binding assay), when the
assays were performed on bovine samples (n = 108) with a
range of low, medium and high concentrations of Hp (Fig. 5).
These samples were selected so that they gave a reading in the
Hb-Hp binding assay of above 0.03 g/L, which is the limit of
detection of this assay. The same data plotted in a Bland-
Altman plot showed a slight bias with the Hp-Hb giving a mean
of 0.07 g/L less than the result of the IT assay (Fig. 6).
Discussion
This IT assay for bovine Hp has been established, validated
and can be employed for the rapid analysis of this major APP
in cattle. Using a specific antiserum for bovine Hp, the
analysis, performed on an automated biochemical analyser
allows routine analysis of this biomarker of infection and in-
flammation to be incorporated into health assessment of both
dairy and beef cattle. The assay has comparable levels of pre-
cision and accuracy to the Hp-Hb activity assay that has been
used in laboratories based on the method first described by
(Eckersall et al. 1999). The precision of the IT assay was 5%
or less for intra assay CVs, and 8.1% or less for inter-assay
CVs, comparable to the Hp-Hb binding assay. The accuracy
was not determined in the previous Hp-Hb assay by determi-
nation of recovery, and so cannot be compared to the ITassay.
However, both assays gave comparable results using parallel
dilution curves. Specificity of the IT assay was demonstrated
by the antibody cross-reactivity demonstrated by the
Ouchterlony immunodiffusion gel. At present, the cross spe-
cies reactivity of the antiserum has not been assessed, though
as the antibody was raised in sheep, it is unlikely to react with
ovine Hp. Interference by free Hb was evident at a concentra-
tion of 4 g/L with a 10% reduction but there was a lower
interference than the Hp-Hb binding assay which a 17% re-
duction in Hp caused by free Hb in serum at a similar concen-
tration. Samples with gross haemolysis should not be analysed
with the IT Hp assay. Bilirubin and lipaemia had minimal
effect on the IT Hp assay. Specificity by antibody cross-
reactivity was only possible in the IT assay, which as it relies
on the antibody specificity, was not possible in the Hp-Hb
binding assay.
Definition of the LoQ for the IT assay is valuable for mea-
suring Hp in bovine species as it has been long established that
the Hp concentration in serum from healthy cattle is very low,
indeed undetectable in some assays and would not be in the
range for this IT analysis on a biochemical analyser. This was
established in early investigations of bovine Hp (Young et al.
1995; Eckersall and Conner 1990) and can be seen in Fig. 1 of
Table 3 Recovery of haptoglobin added to blank sample (n = 4)
Expected Hp (g/L) Observed Hp (g/L)
Mean ± SD
Recovery (%)
0.93 1.02 ± 0.07 109
0.47 0.52 ± 0.02 112
0.23 0.23 ± 0.005 99
0.12 0.09 ± 0.001 76
Average = 99
Table 1 Intra-assay precision (n = 6) of immunoturbidimetric assay for
bovine haptoglobin
QC sample Mean (g/L) SD CV %
Low QC 0.21 0.009 4.1
High QC 1.08 0.54 5.0
Table 2 Inter-assay precision (n = 6) of immunoturbidimetric assay for
bovine haptoglobin
QC sample Mean (g/L) SD CV %
Low QC 0.15 0.011 7.4
High QC 1.09 0.088 8.1
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this report where there is no antibody reaction seen in the
Ouchterlony gel where the sample is serum from a healthy
cow. In this assay, the LoQ is 0.033 g/L and the reference
range for Hp in serum from healthy animals is therefore <
0.033 g/L. Any result above, this would indicate the presence
of an acute phase response. A more relevant figure would be a
clinical decision point to aid interpretation and provide an
indication when therapeutic intervention would be necessary.
It would be useful if all assays for Hp, especially for species
where the concentration in healthy animals is low or undetect-
able to have a well-defined LoQ and a clinical decision point.
To define a clinical decision point is outwith the scope of this
report and will require further trials with substantially more
samples from cattle with clinical and sub-clinical disease. The
replicates for LoQ were lower than ideal to conserve the anti-
serum reagent but do provide an indication of the sensitivity of
the assay. If an IT assay were to be developed as a diagnostic
kit, then this and the other validation parameters should be
reassessed.
The detection and monitoring of sub-clinical disease using
Hp will need assays with lower LoQ, such as those using the
ELISA format, first noted in the literature over 20 years
Fig. 4 (a Top panel) The effect of free haemoglobin on the
immunoturbidimetric assay for haptoglobin. (b Middle panel) The
effect of bilirubin on the immunoturbidimetric assay for haptoglobin. (c
Bottom panel) The effect of lipaemia on the immunoturbidimetric assay
for haptoglobin
Fig. 3 Linearity determined by dilution of a bovine serum with a high-
concentration haptoglobin and serially diluted and then assayed by the
immunoturbidimetric assay for haptoglobin
Fig. 2 Accuracy determined by spiking Hp to zero standard and assayed
with the immunoturbidimetric assay for haptoglobin
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(Young et al. 1995) and more recently (Hiss et al. 2004; Cooke
and Arthington 2013; Thomas et al. 2016). Although a limit of
detection was reported in the earliest of these (Young et al.
1995), it was given in units of % Hb binding capacity (8 mg%
HbBC) and not converted to grams per litre making compar-
ison difficult to the LoQ for this ITassay. A LoD of 0.07 mg/L
for an Hp ELISA, rather than LoQ, was reported by Hiss et al.
(2004) which is 470 less than the LoQ of the IT assay dem-
onstrating the greater sensitivity of the ELISA. When an
ELISA was compared to a Hp-Hb assay for Hp in bovine
samples, the ELISAmeasured a level of 0.11 μg/mL in serum,
but a Hp-Hb binding assay was reported as giving a negative
value of negative 10.35 μg/mL. This should have been report-
ed as less than the LoD, but this was not defined (Cooke and
Arthington 2013). The level of 0.11 μg/mL as reported is 300-
fold less than the LoQ of the IT assay. However, the ELISA
format is not suitable for most diagnostic laboratories while
the IT method described here would be easily incorporated
into a bovine health profile. Immunoturbidimetric assays can
be adapted by using a latex enhanced approach and can reduce
LoQ by around 10-fold. Whether this would be enough to
allow monitoring of small changes in Hp concentration in
assessment of low-level changes and whether this would be
relevant to clinical diagnosis is a question that can be ad-
dressed by further development of a suitable high sensitivity
assay.
Although IT assays were first described over 30 years ago
(Price et al. 1983), there have been few recent reports of their
development, despite the ITassay being the mainmethod used
for rapid measurement of high abundance proteins of serum in
human clinical biochemistry laboratories. A valuable excep-
tion to this was the description of assays for 14 human serum
proteins, including human Hp (Ledue et al. 2002), while our
previously described IT assay for canine C-reactive protein
(Eckersall et al. 1991) has recently led to commercial assays
for veterinary diagnostic laboratories (Hillstrom et al. 2014;
Hindenberg et al. 2017). Probably the main reason for limited
description of IT assays in the literature is that most work on
these methods is pursued by commercial diagnostic compa-
nies, who retain the assay details within the company for in-
tellectual property reasons. It is known that IT assays can be
run with antibody against a heterologous species, and IT as-
says for human proteins such as CRP are known to work for
canine CRP (Klenner et al. 2010). It is possible that assays
based on antiserum to human Hp would be effective in mea-
suring this APP in bovine serum as has been reported for
canine and equine serum (Tecles et al. 2007; Wiedmeyer and
Solter 1996). However, it is always preferable to use a species-
specific antiserum in IT assays, not least because changing
batches of non-species specific antiserum can have major con-
sequences on an established procedure.
While the early and low-level concentration of Hp in serum
can already be detected by ELISA, this technology more suit-
ed to research projects than to the high-throughput clinical
pathology laboratories where automation of analysis is impor-
tant. However, the easy automation of the IT assay means that
Fig. 6 Bland-Altman difference plot for Hp concentrations in bovine
serum/plasma samples measured with immunoturbidimetric method and
Hp = Hb binding assay (n = 113). The dashed line is the mean of the
difference between assay method results in Hp concentration (− 0.07 g/L)
and the dotted lines are the mean ± 1.96 SD from the mean of this
difference being 0.32 g/L and − 0.47 g/L respectively
Fig. 5 Correlation of bovine Hp estimated by immunoturbidimetric assay
with bovine Hp estimated by Hp-Hb binding assay (n = 108)
Table 4 Limit of quantification determined as the lowest concentration
of Hp in a serially diluted, low Hp sample where the total error (TE) was
less than allowable total error (TEa) of 26.9%
Expected Hp
concentration (g/L)
Mean observed Hp
concentration (g/L)
SD (g/L) TE (%) TE < TEa
0.133 0.136 0.0073 12.8 Yes
0.066 0.059 0.0084 26.2 Yes
0.033 0.028 0.0054 25.4 Yes
0.016 0.047 – 193* No
*TE=Bias as not repeated to conserve antiserum reagent
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it can have wide applications in comparative clinical patholo-
gy laboratories. In species where Hp is present in measurable
concentration in healthy animals such as dog, pig and human,
the Hb-Hp binding assay can be used for this purpose, but the
introduction of the automated IT assay will allow low-level
change in Hp concentration to be assessed in cattle.
Direct comparison of this novel IT assay with the
established Hp-Hb binding assay using 108 bovine serum
samples using correlation and regression analyses showed that
the IT assay gives equivalent results to that of the Hp-Hb
assay, and it is therefore the recommendation of the authors
that the IT assay gradually replace the previously accepted
Hp-Hb assay. The Bland-Altman analysis revealed a minimal
negative bias of 0.07 g/L. This bovine Hp assay has the po-
tential to be included in bovine health assessment profiles,
being in a format that enables inclusion in the workflow of
diagnostic laboratories including use on analysers that are
limited to two reagents. The IT assay could be able to detect
the early stages of an acute phase reaction and such early
changes are detectable throughout a herd, it could indicate
the presence of low level of infection or inflammation that
would allow early intervention at both individual and herd
level to restore the health and the production of milk or meat.
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